GlassScriptPhysician profile
Robert Douglas Hardy
NPI 1588623615
$115,560.38
in general payments reported to CMS, 2019-2025
25 companies · $23K in 2025
The $23K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $3,214 · 2021: $149 · 2022: $12K · 2023: $15K · 2024: $37K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $11K · Travel and Lodging: $7,175 · Consulting Fee: $3,230 · Education: $45.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,936.25 |
| Food and Beverage | $10,667.92 |
| Travel and Lodging | $7,175.48 |
| Consulting Fee | $3,230.00 |
| Education | $45.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $56,032.99 | 2020-2025 | Biktarvy, Sunlenca |
| Merck Sharp & Dohme LLC | $52,014.68 | 2019-2025 | Zerbaxa, Pifeltro, Delstrigo |
| Viiv Healthcare Company | $4,822.14 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Theratechnologies INC. | $1,051.26 | 2019-2025 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $370.80 | 2019-2023 | Nuzyra |
| Emd Serono, INC. | $285.68 | 2024-2025 | |
| Janssen Biotech, INC. | $109.54 | 2023 | Symtuza |
| Comsort, INC | $100.00 | 2019 | |
| Novo Nordisk INC | $99.68 | 2023-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $71.78 | 2022-2024 | Spravato |
| Shionogi INC | $71.08 | 2020-2022 | |
| Pfizer INC. | $69.93 | 2025 | |
| Astellas Pharma US INC | $62.76 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $50.14 | 2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $46.66 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.37 | 2023 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $41.48 | 2025 | |
| Lilly USA, LLC | $40.95 | 2025 | Mounjaro, Zepbound |
| Mayne Pharma Commercial LLC | $37.04 | 2019 | |
| Allergan, INC. | $35.89 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $27.22 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.17 | 2024 | Caplyta |
| Ferring Pharmaceuticals INC. | $18.24 | 2022 | |
| Cranial Technologies, INC | $16.10 | 2025 | Doc Band |
| Alkermes, INC. | $13.80 | 2023 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.